By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today said that it has begun enrollment in a pivotal study of its multi-marker, molecular colorectal cancer screening test.

The Madison, Wis.-based firm said that it plans to carry out the study at 60 sites in the US and Canada. It expects those sites will enroll more than 10,000 patients between the ages of 50 and 84 who are at average risk for developing colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.